Dermagnostix

What Dermagnostix does

Dermagnostix GmbH is a Freiburg im Breisgau, Germany-based molecular diagnostics company that develops automated gene-expression tests to support differential diagnosis of inflammatory skin diseases. Founded in 2016 by Prof. Dr. Natalie Garzorz-Stark (CEO) and Ludwig Gutzweiler (CTO) as a spin-off from academic dermatology research, the company operates a razor-and-blade platform built around the LabDisk-Analyzer instrument and proprietary single-use LabDisk consumables. Its lead commercial product, PsorX-LabDisk (CE-IVD), is the first molecular test to quantitatively distinguish psoriasis from eczema by measuring NOS2 and CCL27 gene expression in FFPE skin samples, reporting 92% sensitivity, 100% specificity, and 0.97 AUC in peer-reviewed validation. The company has extended into a TargetDisk research-use line (Erysk-TargetDisk for T-cell pathways, PE-TargetDisk for fresh-skin profiling) and discloses a pipeline of LymphX-LabDisk (mycosis fungoides differentiation), PatternX-LabDisk (molecular pattern diagnostics), and PsorXD-DermDisk (point-of-care testing). The fully automated sample-to-answer workflow delivers results in 1-2 hours with minimal user training and complies with the EU In Vitro Diagnostic Regulation.

Dermagnostix generates revenue through sales of the LabDisk-Analyzer instrument to dermatopathology laboratories and dermatology practices, recurring consumable revenue from single-use LabDisks, per-test fees through partner laboratories that perform testing for referring clinicians, and a third-party hardware revenue stream from the Dialunox-acquired fluorescence detector products. The company sells direct in DACH (Germany, Austria) and distributes exclusively through Axon Lab AG across Austria, Switzerland, Poland, Czech Republic, Slovakia, Slovenia, and Croatia, with a December 2025 strategic partnership with Euroimmun intended to broaden geographic and channel reach. Pricing is quote-based and not publicly disclosed; PsorX is not yet covered by German statutory health insurance (GKV), constraining adoption speed but remaining positioned as affordable for out-of-pocket patients. Manufacturing is based in Germany, with R&D, instrument integration, and consumable development at the Freiburg headquarters and fluorescence detector production at the acquired Stockach facility.

Name

Dermagnostix

Legal name

Dermagnostix GmbH

Website

https://dermagnostix.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Dermagnostix is a German molecular diagnostics company that develops automated LabDisk-based gene-expression tests for dermatology. It sells the PsorX-LabDisk (CE-IVD) to dermatopathology labs and dermatologists for molecular differentiation of psoriasis and eczema.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dermatopathology (HLAKACAC)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), General & Medical Dermatology (HLAKACAA), Psoriasis & Eczema Specialty Care (HLAKACAL), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Molecular diagnostics
• Dermatology diagnostics
• In vitro diagnostics
• Gene expression analysis
• Dermatopathology solutions

Headquarters

HQ city

Freiburg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. LabDisk Diagnostic Systems: Sale of LabDisk-Analyzer instrument systems to dermatopathology laboratories and dermatology practices, along with proprietary LabDisk consumables (PsorX-LabDisk, PE-TargetDisk, Erysk-TargetDisk) that perform specific molecular diagnostic tests.
2. Diagnostic Testing Services: Partner laboratories perform molecular diagnostic tests using Dermagnostix system and provide results to referring dermatologists and dermatopathology practices.
3. Fluorescence Detector Products: Sale of fluorescence detector technology acquired from Dialunox to external companies and research institutions for various fluorescence measurement applications.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Dermagnostix develops and sells an automated molecular diagnostics platform for dermatology, consisting of the LabDisk-Analyzer instrument and a portfolio of proprietary LabDisk consumable tests. Its flagship CE-IVD certified product, PsorX-LabDisk, performs RT-qPCR analysis of NOS2 and CCL27 gene expression in FFPE skin samples to differentially diagnose psoriasis versus eczema. The company also offers RUO assays (PE-TargetDisk, Erysk-TargetDisk) and operates a partner laboratory network providing diagnostic testing services to dermatologists and dermatopathology labs across Europe.

Product overview

Dermagnostix offers a modular molecular diagnostics platform consisting of the LabDisk-Analyzer (the core automated instrument) and a portfolio of consumable LabDisk products. The main product line includes the PsorX-LabDisk (CE-IVD certified) for differential diagnosis of psoriasis and eczema using FFPE samples, and the TargetDisk product line (PE-TargetDisk and Erysk-TargetDisk, both RUO) for fresh skin samples and FFPE samples respectively. The fully automated system processes samples from preparation to signal detection in approximately 1-2 hours. Pipeline products include LymphX-LabDisk for mycosis fungoides differentiation, PatternX-LabDisk for molecular pattern-based diagnostics, and PsorXD-DermDisk for point-of-care use. The platform is designed for dermatology and dermatopathology laboratories seeking molecular insights to complement traditional histology.

Differentiator

Problem solved

Functional benefit

Brands

• PsorX-LabDisk: The first molecular test for the differential diagnosis of psoriasis and eczema, analyzing the expression of NOS2 and CCL27 marker genes.
• LabDisk-Analyzer
• PE-TargetDisk
• Erysk-TargetDisk

Products and services

• LabDisk-Analyzer
• PsorX-LabDisk The world's first CE-IVD certified molecular diagnostic test for the differential diagnosis of psoriasis and eczema. It analyzes the expression of NOS2 and CCL27 marker genes in FFPE skin samples using fully automated RT-qPCR on the LabDisk-Analyzer, with reported 92% sensitivity, 100% specificity, and 0.97 AUC. It is intended for dermatopathologists, pathology laboratories, and dermatologists seeking objective molecular insights to complement histology.
• PE-TargetDisk A research-use-only (RUO) molecular assay enabling measurement of the biomarkers NOS2 and CCL27 from fresh human skin samples. It supports a deeper understanding of the biological patterns of the inflammatory dermatoses psoriasis and eczema and delivers objective, biologically grounded information quickly and simply, targeting point-of-care use in dermatology practices.
• Erysk-TargetDisk A research-use-only (RUO) molecular assay for analysis of selected biomarker genes including LCK and HOMER1 in FFPE samples, which have been studied for their role in T-cell-mediated pathways. It empowers scientists and research users to understand the molecular mechanisms underlying skin function using the TargetDisk product line.

Quantifiable outcome

• 92% sensitivity, 100% specificity, 0.97 AUC for psoriasis vs eczema differentiation
• +3 more outcomes

Named customers13 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• EuroimmuncoreStrategic or Co-development Partner · 18 December 2025Strategic partnership announced December 2025 with Euroimmun, a globally leading provider of medical diagnostic solutions. Collaboration focused on molecular diagnostics of skin diseases, combining Dermagnostix's LabDisk platform with Euroimmun's established diagnostic expertise and global distribution network.
• Axon Lab AGcoreChannel Partner/ Reseller/ Distributor · 1 September 2025Exclusive distribution partnership effective September 1, 2025. Axon Lab AG, a Swiss company with over 35 years of experience, serves as exclusive distributor for Austria, Switzerland, Poland, Czech Republic, Slovakia, Slovenia, and Croatia. Provides comprehensive services including consulting, installation, training, and technical support throughout the diagnostic process chain.
• Dialunox GmbH i.L.coreTechnology or Integration · 1 July 2025Acquisition and continuation of fluorescence detector technology from Dialunox GmbH i.L. (Stockach) effective July 1, 2025. Includes transfer of facilities, expertise, and IP rights. Fluorescence detector is a key component of LabDisk-Analyzer for reading PCR signals. Dermagnostix continues supplying existing Dialunox customers with fluorescence measurement products.
• Spindiag GmbHcoreTechnology or Integration · 1 February 2024Acquisition of facilities, expertise, and IP rights from former Spindiag GmbH in February 2024. This strategic acquisition secured critical manufacturing capabilities, technical knowledge, and intellectual property foundational to Dermagnostix's microfluidic diagnostic platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Castle Biosciences: US-based molecular diagnostics company specializing in dermatology and other cancers (e.g., DecisionDx-Melanoma). Most directly comparable peer in terms of dermatology-focused proprietary gene-expression testing sold to pathology/dermatology providers.
• DermTech: US-based non-invasive skin genomics company offering molecular assays (e.g., pigmented lesion assay) used by dermatologists. Comparable because it pairs proprietary skin-sample molecular biomarkers with a dermatology-focused commercial motion, though DermTech focuses on melanoma risk rather than inflammatory disease.
• Veracyte: Molecular diagnostics company with a dermatology franchise (e.g., myPath Melanoma) and broader urology/thyroid/oncology menu. Closely comparable business model of proprietary gene-expression tests sold into pathology workflows with razor/blade economics.

Broad incumbents

• Myriad Genetics: Established molecular diagnostics incumbent with dermatology-adjacent offerings (e.g., Vectra for inflammatory disease) and a broad oncology pipeline. Larger scale, broader portfolio and full reimbursement coverage make it the most relevant broad incumbent for Dermagnostix's diagnostic category.
• QIAGEN: Global molecular diagnostics and sample-technology vendor with PCR-based workflows, IVD offerings, and dermatology-relevant companion diagnostic capability. Provides the broad-incumbent reference point for what scale molecular diagnostics commercialization looks like and is the most credible potential competitive entrant in Europe.
• Bio-Techne: Life science tools and diagnostics company with proprietary biomarker and assay content (including the ProteinSimple and ExoDx franchises). Comparable through its biomarker-driven diagnostic menu and reagent-based business model.
• Hologic: Diversified diagnostics and women's health company with molecular diagnostic capabilities (e.g., Panther system). Represents the broad-incumbent ceiling for IVD platform scale and the type of strategic partner that could acquire or partner with a specialty dermatology molecular diagnostics player.
• Euroimmun (PerkinElmer/Revvity): Global medical diagnostics provider (now part of Revvity) with deep dermatology and autoimmune diagnostics portfolio. Already Dermagnostix's strategic partner (Dec 2025), Euroimmun is also the most natural broad-incumbent peer and a potential channel for Dermagnostix's international expansion.
• Genomic Health (Exact Sciences): Acquired by Exact Sciences, the Oncotype DX franchise pioneered gene-expression testing in oncology with a pathology-channel commercial model. Provides the most relevant precedent for how a specialty molecular diagnostics company can scale via reimbursement wins and broad-channel partnerships.

Emerging players

• HTG Molecular Diagnostics: Smaller molecular diagnostics player focused on gene-expression profiling and biomarker assays for oncology and other indications. Comparable as a focused emerging player with similar biomarker-assay economics but a different therapeutic focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@dermagnostixgmbh
• Facebookfacebook.com/profile.php?id=61573923427387
• LinkedInlinkedin.com/company/dermagnostix
• Instagraminstagram.com/dermagnostix

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dermagnostix